Clinical Trials Logo

Clinical Trial Summary

This randomized, active-controlled, multicenter, open-label, Phase III study is designed to investigate the efficacy and safety of alectinib compared with platinum-based in the adjuvant setting. Participants in the experimental arm will receive alectinib at 600 mg orally twice daily (BID) taken with food for 24 months.

Participants in the control arm will receive one of the protocol specified platinum based chemotherapy regimens for 4 cycles. Following treatment completion, participants will be followed up for their disease until disease recurrence. At the time of disease recurrence, participants will enter a survival follow-up until death, withdrawal of consent or study closure, whichever occurs earlier.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03456076
Study type Interventional
Source Hoffmann-La Roche
Contact Reference Study ID Number: BO40336 www.roche.com/about_roche/roc
Phone 888-662-6728 (U.S. and Canada)
Email global-roche-genentech-trials@gene.com
Status Recruiting
Phase Phase 3
Start date August 16, 2018
Completion date September 30, 2026

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02864394 - Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033) Phase 3
Completed NCT01953913 - Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation Phase 3
Recruiting NCT02847377 - A Positron Emission Tomography (PET) Imaging Agent [18F]-ODS2004436 as a Marker of EGFR Mutation in Subjects With NSCLC Early Phase 1
Recruiting NCT02934360 - TR(ACE) Assay Clinical Specimen Study N/A
Recruiting NCT02926768 - Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors Phase 1/Phase 2
Completed NCT01160744 - A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC) Phase 2
Active, not recruiting NCT00921310 - Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT01860898 - A Phase I Study of iPS Cell Generation From Patients With COPD N/A
Completed NCT01022671 - Study of Camtobell Inj (Belotecan) on Weekly Schedule in Non-small Cell Lung Cancer (NSCLC) Patients Previously Treated With Chemotherapy Phase 2
Completed NCT00932893 - An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene Phase 3
Active, not recruiting NCT00690963 - Individual Boosting in Non-Small Cell Lung Cancer Using Hypofractionation, Intensity-modulated Radiation Therapy and Respiratory Gating Phase 1/Phase 2
Recruiting NCT00797238 - DNA Repair Genes and Outcomes in Patients With Stage III NSCLC N/A
Completed NCT00531401 - Study of Salirasib to Treat Non-Small Cell Lung Cancer Phase 2
Terminated NCT00558922 - A Phase 1-2 XIAP Antisense AEG35156 With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer Phase 1/Phase 2
Terminated NCT00558636 - A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC) Phase 3
Terminated NCT00535275 - NSCLC Relapse Therapy After Surgery and Peri-operative Chemotherapy Phase 3
Terminated NCT00539331 - Phase I/II Study of AZD2171 in Combination With Paclitaxel/Carboplatin in Japanese Non-Small Cell Lung Cancer Patients Phase 1
Completed NCT00600587 - Induction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC) Phase 2
Terminated NCT00532025 - Sorafenib in Resected Non-small Cell Lung Carcinoma Phase 2
Withdrawn NCT00256841 - Hypo-Hyperfractionated Chest Radiation for Non Small Cell Lung Cancer With Taxotere/Xeloda Combination Chemotherapy Phase 1/Phase 2